|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
12/6/2012 7:44:44 AM
Drug companies and universities are spending 55.6 million euros ($72.7 million) to develop a bank of stem cells to use in testing potential treatments for hard-to- treat diseases. The effort, known as Stembancc and managed by the University of Oxford in England, will focus on generating 1,500 induced pluripotent stem cell lines, researchers said at a London news conference. The cells will be used by drugmakers including Pfizer Inc. (PFE), Sanofi (SAN) and Roche Holding AG (ROG) to test treatments for peripheral nervous disorders, pain, dementia, migraine, autism, schizophrenia, bipolar disorder and diabetes and to perform toxicology tests. “This is a pioneering effort,” said Zameel Cader, a neurologist at Oxford and one of Stembancc’s leaders. “We want to be a flagship project within Europe.” The researchers chose to use induced pluripotent stem cells, which are adult stem cells that can be reprogrammed to generate any type of cell, because they probably have the genetic information needed for studying the diseases, Cader said. John Gurdon of the U.K. and Shinya Yamanaka of Japan won the 2012 Nobel Prize in Physiology or Medicine for work on induced pluripotent stem cells.
|
|
|
|
|
|
|
|
|
|
|